Advertisement
BAX vs STE
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BAX is a Hold and STE is a Hold.
Aroon Indicator for BAX shows an upward move is likely
BAX's Aroon Indicator triggered a bullish signal on October 19, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 210 similar instances where the Aroon Indicator showed a similar pattern. In 143 of the 210 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 68%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 30, 2026. You may want to consider a long position or call options on BAX as a result. In 55 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for BAX just turned positive on September 30, 2026. Looking at past instances where BAX's MACD turned positive, the stock continued to rise in 24 of 45 cases over the following month. The odds of a continued upward trend are 53%.
BAX moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where BAX advanced for three days, in 165 of 290 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
Bearish Trend Analysis
The 10-day RSI Indicator for BAX moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 22 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 67%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 10-day moving average for BAX crossed bearishly below the 50-day moving average on September 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
BAX broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. BAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.082) is normal, around the industry mean (4.887). P/E Ratio (-12.072) is within average values for comparable stocks, (35.995). BAX's Projected Growth (PEG Ratio) (36.677) is very high in comparison to the industry average of (4.456). Dividend Yield (0.002) settles around the average of (0.006) among similar stocks. P/S Ratio (1.057) is also within normal values, averaging (56.074).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
STE in upward trend: price rose above 50-day moving average on October 15, 2026
STE moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend. In 27 of 44 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 61%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 08, 2026. You may want to consider a long position or call options on STE as a result. In 44 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 46%.
The Moving Average Convergence Divergence (MACD) for STE just turned positive on September 29, 2026. Looking at past instances where STE's MACD turned positive, the stock continued to rise in 25 of 47 cases over the following month. The odds of a continued upward trend are 53%.
Following a +3.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where STE advanced for three days, in 152 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 48%.
The Aroon Indicator entered an Uptrend today. In 98 of 200 cases where STE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 49%.
Bearish Trend Analysis
The 10-day RSI Indicator for STE moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 21 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 55%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 57%.
STE broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. STE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 66 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.003) is normal, around the industry mean (2.908). P/E Ratio (27.004) is within average values for comparable stocks, (2.616). Projected Growth (PEG Ratio) (1.760) is also within normal values, averaging (11.052). Dividend Yield (0.012) settles around the average of (0.009) among similar stocks. P/S Ratio (3.423) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 84 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
BAX | STE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 18 | 24 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 95 Overvalued | 76 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 84 | |
SMR RATING 1..100 | 94 | 66 | |
PRICE GROWTH RATING 1..100 | 50 | 50 | |
P/E GROWTH RATING 1..100 | 59 | 74 | |
SEASONALITY SCORE 1..100 | 85 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
STE's Valuation (76) in the Medical Specialties industry is in the same range as BAX (95). This means that STE’s stock grew similarly to BAX’s over the last 12 months.
STE's Profit vs Risk Rating (84) in the Medical Specialties industry is in the same range as BAX (100). This means that STE’s stock grew similarly to BAX’s over the last 12 months.
STE's SMR Rating (66) in the Medical Specialties industry is in the same range as BAX (94). This means that STE’s stock grew similarly to BAX’s over the last 12 months.
STE's Price Growth Rating (50) in the Medical Specialties industry is in the same range as BAX (50). This means that STE’s stock grew similarly to BAX’s over the last 12 months.
BAX's P/E Growth Rating (59) in the Medical Specialties industry is in the same range as STE (74). This means that BAX’s stock grew similarly to STE’s over the last 12 months.
| BAX | STE | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 67% | 2 days ago 55% |
| Stochastic ODDS (%) | 2 days ago 71% | 2 days ago 57% |
| Momentum ODDS (%) | 2 days ago 65% | 2 days ago 46% |
| MACD ODDS (%) | 2 days ago 53% | 2 days ago 53% |
| TrendWeek ODDS (%) | 2 days ago 60% | 2 days ago 51% |
| TrendMonth ODDS (%) | 2 days ago 64% | 2 days ago 47% |
| Advances ODDS (%) | 8 days ago 57% | 9 days ago 48% |
| Declines ODDS (%) | 2 days ago 68% | 2 days ago 57% |
| BollingerBands ODDS (%) | 2 days ago 65% | 2 days ago 61% |
| Aroon ODDS (%) | 2 days ago 68% | 2 days ago 49% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BAX’s FA Score shows that 0 FA rating(s) are green while STE’s FA Score has 0 green FA rating(s).
- BAX’s FA Score: 0 green, 5 red.
- STE’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BAX’s TA Score shows that 5 TA indicator(s) are bullish while STE’s TA Score has 5 bullish TA indicator(s).
- BAX’s TA Score: 5 bullish, 5 bearish.
- STE’s TA Score: 5 bullish, 4 bearish.
Price Growth
BAX (@Pharmaceuticals: Other) experienced а +0.85% price change this week, while STE (@Medical/Nursing Services) price change was +1.37% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.97%. For the same industry, the average monthly price growth was -2.43%, and the average quarterly price growth was +7.73%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -3.67%. For the same industry, the average monthly price growth was -9.96%, and the average quarterly price growth was -11.00%.
Reported Earning Dates
BAX is expected to report earnings on Oct 29, 2026.
STE is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+0.97% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-3.67% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
STE and
Correlation & Price change
A.I.dvisor indicates that over the last year, STE has been loosely correlated with SYK. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if STE jumps, then SYK could also see price increases.